Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any primary ciliary dyskinesia in which the cause of the disease is a mutation in the CFAP54 gene.
Features include always present findings: Bronchiectasis, Asthma, Recurrent bronchitis, and Productive cough and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 4 | Bronchiectasis, Asthma, Recurrent bronchitis |
CFAP54 encodes cilia and flagella associated protein 54 (3,096 aa). Required for assembly and function of cilia and flagella Highest expression in Testis (4.0 TPM) and Pituitary (1.4 TPM).
Ciliary dyskinesia, primary, 54 is strongly associated with mutations in the CFAP54 gene on chromosome 12.
CFAP54 is classified as a druggable target with score 0.0.
Genetic testing for CFAP54 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for ciliary dyskinesia, primary, 54 has been reported in the published literature.
Phenotype severity distribution: 9 always present features.
No clinical trials have been registered for ciliary dyskinesia, primary, 54.
19 publications have been identified in PubMed for ciliary dyskinesia, primary, 54. Research spans Epidemiology / Natural History (26%), Diagnostic / Biomarker (16%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 5 | 26% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 12:50 AM UTC
Online Mendelian Inheritance in Man
Common questions about ciliary dyskinesia, primary, 54
Testing and diagnosis research
3 |
16% |
Research summaries | 3 | 16% |
Laboratory research | 3 | 16% |
Patient case studies | 2 | 11% |
New treatment approaches | 2 | 11% |
Clinical study results | 1 | 5% |
Khalaili L (2026). [PMID: 40610053](https://pubmed.ncbi.nlm.nih.gov/40610053/). *Eur Respir J*. [Epidemiology / Natural History]
Wirtz MM (2026). [PMID: 41509703](https://pubmed.ncbi.nlm.nih.gov/41509703/). *Case Rep Genet*. [Case Report / Case Series]
Benjamin AT (2026). [PMID: 41721661](https://pubmed.ncbi.nlm.nih.gov/41721661/). *Lung India*. [Clinical Trial Publication]
Thawanaphong S (2026). [PMID: 42104487](https://pubmed.ncbi.nlm.nih.gov/42104487/). *Allergy Asthma Clin Immunol*. [Case Report / Case Series]
Karavasiloglou N (2026). [PMID: 42203237](https://pubmed.ncbi.nlm.nih.gov/42203237/). *Eur Respir Rev*. [Review / Meta-Analysis]
Xie XH (2025). [PMID: 40467998](https://pubmed.ncbi.nlm.nih.gov/40467998/). *J Hum Genet*. [Epidemiology / Natural History]
Magee K (2025). [PMID: 39695270](https://pubmed.ncbi.nlm.nih.gov/39695270/). *J Hum Genet*. [Basic Science / Preclinical]
Liu T (2025). [PMID: 39686771](https://pubmed.ncbi.nlm.nih.gov/39686771/). *Asian J Androl*. [Gene Therapy / Novel Therapeutics]
Burns G (2025). [PMID: 41088162](https://pubmed.ncbi.nlm.nih.gov/41088162/). *Orphanet J Rare Dis*. [Diagnostic / Biomarker]
Karakoç E (2025). [PMID: 40142748](https://pubmed.ncbi.nlm.nih.gov/40142748/). *J Clin Med*. [Diagnostic / Biomarker]